Market Place
Sourcing Support
Daiichi Sankyo to Showcase TURALIO® at CTOS for Giant Cell Tumor
13 Nov 2024 //
BUSINESSWIRE
Daiichi Sankyo Provides Update on CHMP Review of Pexidartinib, a CSF1R
29 Jun 2020 //
DAIICHISANKYO
EMA recommends eight new medicines, refuses one
27 Jun 2020 //
RAPS
Daiichi Sankyo Provides Update on CHMP Review of Pexidartinib, a CSF1R Inhibitor
26 Jun 2020 //
BUSINESSWIRE
Daiichi Sankyo scores landmark FDA OK for rare tumor drug albeit restrictions
06 Aug 2019 //
ENDPTS
Daiichi Sankyo`s Turalio becomes first FDA-approved therapy for rare tumour
06 Aug 2019 //
PHARMAFILE
FDA approves first therapy for rare joint tumor
03 Aug 2019 //
FDA
FDA approves first therapy for rare joint tumor
02 Aug 2019 //
PR NEWSWIRE
FDA Approves Daiichi Sankyo`s TURALIO™ (pexidartinib)
02 Aug 2019 //
PR NEWSWIRE
Daiichi Sankyo`s Pexidartinib Demonstrated Further Improvement
04 Jun 2019 //
PR NEWSWIRE
FDA Oncologic Drugs Advisory Committee Votes of Daiichi Sankyo`s Pexidartinib
14 May 2019 //
PR NEWSWIRE
EMA Validates Daiichi Sankyo’s MAA for pexidartinib
04 Apr 2019 //
PHARMABIZ
Daiichi`s ph3 study of pexidartinib shows clinical improvement in TGCT patients
05 Jun 2018 //
PHARMABIZ
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.